You are here

Our science / Clinical Trials / Find a Trial / NCT00174343

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Back to Search Print Save as PDF Bookmark Trial

NCT00174343

Last updated on August 9, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Bordeaux, , France
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non
inflammatory, operable, hormonal receptors positive

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal
receptors negative

NCT00174343
Pfizer
Completed
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
NCT02315066
All Genders
18+
Years
Multiple Sites
Neoplasms
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
NCT02222922
All Genders
18+
Years
Multiple Sites
Kidney Neoplasms
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
NCT00375674
All Genders
18+
Years
Multiple Sites
Early Breast Cancer
Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer
NCT03499353
All Genders
18+
Years
Multiple Sites
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Neoplasms
Drug: exemestane (Aromasin®)
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
46
September 2006
Not Provided

Inclusion Criteria:

  • Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive

Exclusion Criteria:

  • Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative
Sexes Eligible for Study: Female
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00174343
971-ONC-0028-095
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now